Show simple item record

dc.contributor.authorHernando Ortiz, Ainara ORCID
dc.contributor.authorEraso Barrio, María Elena ORCID
dc.contributor.authorJauregizar Albonigamayor, Nerea ORCID
dc.contributor.authorDe Groot, Piet W. J.
dc.contributor.authorQuindós Andrés, Guillermo
dc.contributor.authorMateo Alesanco, Estibaliz ORCID
dc.date.accessioned2024-05-06T16:36:24Z
dc.date.available2024-05-06T16:36:24Z
dc.date.issued2024-01
dc.identifier.citationMicrobiology Spectrum 12(1) : (2024) // Article ID e0208623es_ES
dc.identifier.issn2165-0497
dc.identifier.urihttp://hdl.handle.net/10810/67542
dc.description.abstractThe multidrug-resistant Candida auris is a global health emergency, being responsible for outbreaks of invasive candidiasis worldwide. Limited effective therapeutic options make it difficult to treat this emerging pathogen. In this context, combinations of different antifungal drugs are considered a promising therapeutic alternative. The aim of this work was to analyze the antifungal activity of combinations of amphotericin B and echinocandins against five clinical blood isolates of C. auris. One of these isolates showed an aggregative phenotype already described in C. auris species, forming large aggregates of cells that are very difficult to disintegrate. First, the in vitro activity of these drugs was evaluated both in monotherapy and in combination, and results showed synergistic interactions between amphotericin B and echinocandins in most cases, although higher minimum inhibitory concentration (MIC) values were observed against the aggregative isolate compared to non-aggregative counterparts. The most promising drug combinations were then selected for in vivo activity evaluation using a Caenorhabditis elegans model of candidiasis and by determination of survival rates. The combination of amphotericin B and caspofungin showed the strongest protective effect during C. elegans infection with C. auris blood isolates, achieving up to 99% C. elegans survival. Although the MIC values for micafungin were low in vitro, these drug concentrations had no effect in vivo, and the combination of amphotericin B and micafungin was the least effective. The results of this study showed that the combination amphotericin B and echinocandins might be a promising therapeutic approach for the treatment of invasive candidiasis caused by C. auris. Moreover, the nematode C. elegans is a suitable alternative model for screening of new therapeutic agents capable of overcoming multidrug-resistant C. auris infections.es_ES
dc.description.sponsorshipThis research was funded by the Spanish Ministry of Science and Innovation (PID2020-117983RB-I00) and by the Consejería de Educación, Universidades e Investigación of Gobierno Vasco-Eusko Jaurlaritza (IT1607-22). A. Hernando-Ortiz was supported by a PhD grant from the University of the Basque Country (PIF 16/39).es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society of Microbiologyes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2020-117983RB-I00es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleEfficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host modeles_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2023 Hernando-Ortiz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://journals.asm.org/doi/10.1128/spectrum.02086-23es_ES
dc.identifier.doi10.1128/spectrum.02086-23
dc.departamentoesFarmacologíaes_ES
dc.departamentoesInmunología, microbiología y parasitologíaes_ES
dc.departamentoeuFarmakologiaes_ES
dc.departamentoeuImmunologia, mikrobiologia eta parasitologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2023 Hernando-Ortiz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Except where otherwise noted, this item's license is described as © 2023 Hernando-Ortiz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.